Randomised Trial of 3 Artemisinin Combination Therapy for Malaria in Pregnancy

Inclusion Criteria: * Age 18-45 years * Viable pregnancy of any gestation as assessed by ultrasound scanning * Microscopically confirmed uncomplicated malaria (parasitaemia ≥ 5/500 WBC) with Plasmodium falciparum or Mixed infection (i.e. P.falciparum \& P.vivax/ovale/malariae) or Plasmodium vivax/ovale/malariae * Willingness and ability to comply with the study protocol for the duration of the trial * Written informed consent provided * No signs of labour Additional criteria for patients in the detailed pharmacokinetic study group (N=24 in the MAS3 arm): * HCT\>25% (based on field reading i.e. capillary sample) * P.falciparum monoinfection * Agree to stay in the clinic for 7 days * Written consent to participate the detailed PK subgroup Exclusion Criteria: * Known hypersensitivity to the study drugs * P.falciparum asexual stage parasitaemia ≥ 4% RBCs * Clinical or laboratory features of severe malaria based on WHO criteria-Appendix 1 * Gastrointestinal dysfunction that could alter absorption or motility * History or known liver diseases or other chronic diseases (excluding thalassemia \& G6PD deficiency) * Presence of intercurrent illness or any condition which in the judgement of the investigator would place the patient at undue risk or interfere with the results of the study * Splenectomy * Hematocrit (HCT) \<20% (based on field reading i.e. capillary sample) \[ \*NB: Dense mefloquine pharmacokinetic exclusion if HCT \< 25%\] * Taking contraindicated medications * Hist…